AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02526823
Drug: R-CDOP/CDOPE or DBVD chemotherapy regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CDOP:~Rituximab：375mg/m2，ivgtt，D0； PLD 30-40 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CDOPE:~PLD 30-40 mg/m2，ivgtt，D1； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~DBVD:~PLD 15-20 mg/m2，ivgtt，D1； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；
Trial: NCT02174523
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01509677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, once daily, oral administration in the morning after breakfast
Trial: NCT02850263
Drug: Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
Trial: NCT00826358
Drug: ABT-143
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once, please see Arm Description for more details.
Trial: NCT00826358
Drug: ABT-335
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once, see Arm Description for more detail
Trial: NCT00826358
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: once, see Arm Description for more detail
Trial: NCT00112411
Drug: Bronchodilator
RxNorm normalized name: Bronchodilator
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03640052
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule before sleep
Trial: NCT03640052
Drug: LTM1201L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTM1201L capsule before sleep
Trial: NCT03640052
Drug: LTM1201LN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTM1201LN capsule before sleep
Trial: NCT03640052
Drug: LTM1201LB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTM1201LB capsule before sleep
Trial: NCT03640052
Drug: LTM1201LD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTM1201LD capsule before sleep
Trial: NCT03502967
Drug: Hyperpolarized [1-13C] Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of study drug
Trial: NCT03502967
Drug: Hyperpolarized [2-13C] Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of study drug
Trial: NCT02685748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two pills twice a day (instead of aspirin and pantoprazole)
Trial: NCT00328653
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03549871
Drug: Factor (FVIII or FIX) prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection Route of administration: Intravenous
Trial: NCT01656343
Drug: Calcineurin inhibitors (CNI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Intervention
Trial: NCT02867618
Drug: TGR-1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib
Trial: NCT01054937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. administration
Trial: NCT02311439
Drug: FOLFIRINOX + CRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 D1, 2-hour I.V + Irinotecan 180 mg/m2 D1 90-minute I.V. + Leucovorin 200 mg/m2 2- hour I.V, D1,2 + (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need.~In non-progressed cases, will be followed by consolidation concurrent radiotherapy with capecitabine 625 mg/m2 BID.~Radiotherapy :~A fractionated dose of 50.4Gy /28 fractions/15 MeV photon energy generated by Dual-energetic Linear Accelerator.
Trial: NCT04163991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline for IV infusion
Trial: NCT01632241
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
Trial: NCT01133626
Drug: Placebo Nasal Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal aerosol administered daily for 42 days of treatment
Trial: NCT02403635
Drug: ASP2151
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00195520
Drug: Totelle®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01904149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single oral dose (first 8 hours)
Trial: NCT01904149
Drug: Dexketoprofen-single dose
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen single oral dose (first 8 hours)
Trial: NCT01904149
Drug: Dexketoprofen/Tramadol-single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen/Tramadol single oral dose (first 8 hours)
Trial: NCT01904149
Drug: Dexketoprofen-multiple doses
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
Trial: NCT01904149
Drug: Dexketoprofen/Tramadol-multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
Trial: NCT03395951
Drug: Diuretics
RxNorm normalized name: DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation of hemodynamics during diuretics treatment within clinical indication.
Trial: NCT02238431
Drug: Lucrin depot
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle
Trial: NCT02227173
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00460954
Drug: Sinemet® controlled release (Carbidopa/levodopa)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02567682
Drug: GBT440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
Trial: NCT02802241
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00246025
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo capsule, once a day, oral administration
Trial: NCT03730961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT00524615
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg of spironolactone once daily or placebo for 2 months
Trial: NCT01527513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments will be administered by oral route, once-daily, in the evening.
Trial: NCT00004174
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00001155
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01767493
Drug: [18F]Florbetapir PET imaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]Florbetapir and PET imaging
Trial: NCT01598753
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
Trial: NCT01420874
Drug: FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, \& in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
Trial: NCT01119833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Placebo given twice a day during hospital stay for sickle cell pain crisis
Trial: NCT01457950
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: double-blind phase: placebo subcutaneous injection, single dose
Trial: NCT01790282
Drug: estradiol plus progesterone 100 mg IM injection
RxNorm normalized name: estradiol / progesterone Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET
Trial: NCT03887260
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl administration during procedure, calculated per patient's weight and duration of surgery (minutes).
Trial: NCT00035451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, twice daily for 6 months
Trial: NCT01892761
Drug: Renal transplant recipients were allocated to TCL/MMF or to CyA/MMF groups
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03387943
Drug: PLD
RxNorm normalized name: PLD1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of liposomal doxorubicin 35 mg/m2, d1,once every 21days, for 6 cycles.
Trial: NCT02485652
Drug: HM61713
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria.
Trial: NCT03206632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT00546260
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of iv bolus prior to angiography
Trial: NCT00002598
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002598
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00511433
Drug: NOMAC-E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28~for 6 consecutive 28-day menstrual cycles.
Trial: NCT02908685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
Trial: NCT00283426
Drug: Soluble beta-1,3/1,6-glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01065051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT03258281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo administered subcutaneously
Trial: NCT02526524
Drug: Met DR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin delayed-release tablets
Trial: NCT02526524
Drug: Met IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin immediate-release tablets
Trial: NCT02526524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01503606
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clarithromycin 500mg po bid after randomization for one week
Trial: NCT01503606
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clarithromycin 500mg po bid after randomization until delivery
Trial: NCT00789581
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m2
Trial: NCT00789581
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 600 mg/m2
Trial: NCT01046604
Drug: Lovaza group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.
Trial: NCT01783574
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01783574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00666497
Drug: MGCD0103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle
Trial: NCT00666497
Drug: MGCD0103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle
Trial: NCT04421911
Drug: Ketoprofen topical
RxNorm normalized name: ketoprofen topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen topical for 21days
Trial: NCT00256815
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03115853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet for Aliskerin
Trial: NCT01967017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00693017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-400 mg Zonisamide Placebo capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg Zonisamide Placebo daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg Zonisamide Placebo (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)
Trial: NCT01069861
Drug: sildanefil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
Trial: NCT02312232
Drug: levodopa, carbidopa, ODM-104
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03176472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mL liquid formulation placebo
Trial: NCT00825058
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration 12 hours intervals
Trial: NCT02709187
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigational product is prescribed to all of randomized subjects
Trial: NCT03546166
Drug: Picato 0.05% Topical Gel
RxNorm normalized name: Picato 0.05% Topical Gel (Trunk and Extremities Only)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days. In case of treatment failure after 3 months, apply again on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days.
Trial: NCT01847391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet(s) to match GS-6615 administered orally once daily
Trial: NCT04008732
Drug: MED2005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.
Trial: NCT04008732
Drug: Nitrostat 0.6Mg Sublingual Tablet
RxNorm normalized name: Nitrostat 0.6mg Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.
Trial: NCT03848208
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo oral tablet
Trial: NCT03622112
Drug: AZD7594 DPI 55μg/50μg.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A non-steroidal and selective modulator of the GR.
Trial: NCT03622112
Drug: AZD7594 DPI 99 µg/90 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A non-steroidal and selective modulator of the GR.
Trial: NCT03622112
Drug: AZD7594 DPI 198 µg/180 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A non-steroidal and selective modulator of the GR.
Trial: NCT03622112
Drug: AZD7594 DPI 396 µg/360 µg once daily.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A non-steroidal and selective modulator of the GR.
Trial: NCT03622112
Drug: AZD7594 DPI 792 µg/720 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A non-steroidal and selective modulator of the GR.
Trial: NCT03622112
Drug: Placebo for AZD7594 once daily.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for AZD7594
Trial: NCT03622112
Drug: FF 100 µg once daily (open-label)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate
Trial: NCT00820482
Drug: Menopur®, Ferring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 UI/day of Hp-hMG (Menopur®)
Trial: NCT00820482
Drug: rFSH (Gonal®,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
Trial: NCT01571661
Drug: GSK189075A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
Trial: NCT03634566
Drug: N-Acetylecysteine
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
Trial: NCT03634566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer acetate continuous infusion at the same rate for 2 days.
Trial: NCT03872830
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours.
Trial: NCT01147926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to Prucalopride tablet orally once daily.
Trial: NCT00297102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT00320255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered once daily
Trial: NCT06082596
Drug: BEBT-908 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation phase：10 or 15、22.5、33.75、45mg/m2, intravenous drip, firstly single dose, after the observation period, the drug was administered continuously for 1 cycle (21 days), 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week.~Dose expansion phase：15 or 22.5mg/m2，intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week，21 days as cycle.
Trial: NCT03087942
Drug: QAW039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg
Trial: NCT03087942
Drug: QAW39A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg
Trial: NCT03087942
Drug: QAW39A2107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg
Trial: NCT00773786
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 1 week (added to maintenance tiotropium)
Trial: NCT03943550
Drug: RO7049665
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses of RO7049665 will be administered SC.
Trial: NCT03943550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered SC.